Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: GlobeNewswire
GAITHERSBURG, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to employ Gregory Weaver as Altimmune’s Chief Financial Officer effective November 11, 2024. The equity awards were approved on November 6, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Weaver received, in the aggregate, options to purchase 225,000 shares of Altimmune’s common stock, and 75,000 restricted stock units (“RSUs”). The options will have an exercise price equal to the closing price of Altimmune’s common stock on November 11, 2024 (the “Grant Date”). Based on the closing price Altimmune’s common stock on November 8, 2024, Altimmune would issue approximately 172,920 options as inducement awards under its 2018 Inducement Grant Plan, and the balance as incentive stock op
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune Added to Nasdaq Biotechnology IndexGlobeNewswire
- Altimmune Stock Up More Than 25% in a Month: Here's Why [Yahoo! Finance]Yahoo! Finance
- Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders [Yahoo! Finance]Yahoo! Finance
- Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting DisordersGlobeNewswire
- Altimmune to Participate at Two Upcoming Investor ConferencesGlobeNewswire
ALT
Earnings
- 11/12/24 - Beat
ALT
Sec Filings
- 12/11/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form 4
- ALT's page on the SEC website